-
Future Medicinal Chemistry Jan 2020Steroidal prodrugs of nitrogen mustards such as estramustine and prednimustine have proven effective anticancer agents in clinical use since the 1970s. In this work, we...
Steroidal prodrugs of nitrogen mustards such as estramustine and prednimustine have proven effective anticancer agents in clinical use since the 1970s. In this work, we aimed to develop steroidal prodrugs of the novel nitrogen mustard POPAM-NH. POPAM-NH is a melphalan analogue that was coupled with three different steroidal lactams. The new conjugates were preclinically tested for anticancer activity against nine human and one rodent cancer experimental models, and . All the steroidal alkylators showed high antitumor activity, and , in the experimental systems tested. Moreover, these hybrid compounds showed by far superior anticancer activity compared with the alkylating agents, melphalan and POPAM-NH.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HT29 Cells; Humans; Injections, Intraperitoneal; Lactams; Male; Mice; Mice, SCID; Neoplasms, Experimental; Propionates; Steroids; Structure-Activity Relationship
PubMed: 31729254
DOI: 10.4155/fmc-2019-0255 -
Taiwanese Journal of Obstetrics &... Sep 2019
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Mitoxantrone; Prednimustine; Pregnancy
PubMed: 31542101
DOI: 10.1016/j.tjog.2019.07.026 -
Taiwanese Journal of Obstetrics &... Sep 2019
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Mitoxantrone; Prednimustine; Pregnancy
PubMed: 31542075
DOI: 10.1016/j.tjog.2019.07.001 -
Journal of Geriatric Oncology Nov 2015The purpose of this prospective observational study is to evaluate the relation of the comprehensive geriatric assessment (CGA) to tolerability and survival of... (Observational Study)
Observational Study
OBJECTIVES
The purpose of this prospective observational study is to evaluate the relation of the comprehensive geriatric assessment (CGA) to tolerability and survival of multi-agent chemotherapy for curative intent in elderly patients with aggressive non-Hodgkin lymphoma (NHL).
MATERIALS AND METHODS
Patients who were 1) age ≥65 years, 2) newly diagnosed aggressive NHL, and 3) treated with multi-agent chemotherapy within 2 weeks from the time of diagnosis were enrolled from January 2011 to June 2014. Baseline clinical, laboratory, and CGA data being composed of Mini Nutritional Assessment-Short Form (MNA-SF), Korean version of Mini Mental Status Exam, Korean-Geriatric Depression Scale, and Groningen Frailty Index (GFI), were collected and analyzed for the relation to the outcome factors.
RESULTS
Seventy patients were included; the median age was 73.5 years, 27 (38.6%) patients were Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or more, and half of the patients were high or high-intermediate risk by age-adjusted international prognostic index (aaIPI). Most patients received CHOP or CHOP-like chemotherapy. Factors affecting discontinuation of chemotherapy within 12 weeks were poor MNA-SF, poor GFI, poor PS, and presence of B symptom. Among those, poor MNA-SF was independent of other variables in multivariate analysis. Poor MNA-SF, bone marrow involvement, and baseline anemia of hemoglobin<10g /dL were found to be independent factors associated with inferior overall survival whereas aaIPI factors were not.
CONCLUSION
MNA-SF predicted tolerability to multi-agents chemotherapy and overall survival in elderly patients with aggressive NHL who were treated with multi-agent chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Frail Elderly; Geriatric Assessment; Glyoxal; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Multivariate Analysis; Neoplasm Grading; Prednimustine; Prednisone; Prospective Studies; Republic of Korea; Treatment Outcome; Vincristine
PubMed: 26522808
DOI: 10.1016/j.jgo.2015.10.183